YTHDC1‐dependent m6A modification modulated FOXM1 promotes glycolysis and tumor progression through CENPA in triple‐negative breast cancer
Cancer Science · 2024
DOI: 10.1111/cas.16137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Xi Shen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China. Hauptthemen laut MEDLINE: Cell Proliferation, Disease Progression, Forkhead Box Protein M1, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Triple‐negative breast cancer (TNBC) exhibits heightened aggressiveness compared with other breast cancer (BC) subtypes, with earlier relapse, a higher risk of distant metastasis, and a worse prognosis. Transcription factors play a pivotal role in various cancers. Here, we found that factor forkhead box M1 (FOXM1) expression was significantly higher in TNBC than in other BC subtypes and normal tissues. Combining the findings of Gene Ontology (GO) enrichment analysis and a series of experiments, we found that knockdown of the FOXM1 gene attenuated the ability of TNBC cells to proliferate and metastasize both in vivo and in vitro. In addition, Spearman's test showed that FOXM1 significantly correlated with glycolysis‐related genes, especially centromere protein A (CENPA) in datasets (GSE76250, GSE76124, GSE206912, and GSE103091). The effect of silencing FOXM1 on the inhibition of CENPA expression, TNBC proliferation, migration, and glycolysis could be recovered by overexpression of CENPA. According to MeRIP, the level of m6A modification on FOMX1 decreased in cells treated with cycloleucine (a m6A inhibitor) compared with that in the control group. The increase in FOXM1 expression caused by YTHDC1 overexpression could be reversed by the m6A inhibitor, which indicated that YTHDC1 enhanced FOXM1 expression depending on m6A modification. Therefore, we concluded that the YTHDC1‐m6A modification/FOXM1/CENPA axis plays an important role in TNBC progression and glycolysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
- Department of Health Management, The Second Hospital Affiliated to Chongqing Medical University, Chongqing, China.
- Department of Thyroid and Breast Surgery, Wuhan Fourth Hospital, Wuhan, China.
- Department of Stomatology, Shenzhen Hospital, University of Chinese Academy of Sciences, Shenzhen, China.
- Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
ORCID-Profile: Xi Shen, Jianxin Zhong, Feng Liu, Haoran Peng, Nianyong Chen
Zitieren
APA
Shen, X., Zhong, J., Yu, P., Liu, F., Peng, H., & Chen, N. (2024). YTHDC1‐dependent m6A modification modulated FOXM1 promotes glycolysis and tumor progression through CENPA in triple‐negative breast cancer. Cancer Science. https://doi.org/10.1111/cas.16137
Vancouver
Shen X, Zhong J, Yu P, Liu F, Peng H, Chen N. YTHDC1‐dependent m6A modification modulated FOXM1 promotes glycolysis and tumor progression through CENPA in triple‐negative breast cancer. Cancer Science. 2024. doi:10.1111/cas.16137
BibTeX
@article{Shen2024,
author = {Shen, Xi and Zhong, Jianxin and Yu, Pan and Liu, Feng and Peng, Haoran and Chen, Nianyong},
title = {YTHDC1‐dependent m6A modification modulated FOXM1 promotes glycolysis and tumor progression through CENPA in triple‐negative breast cancer},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16137}
}
EUVIMED